Chemotherapeutic antibiotics use in oncology in small animals: Review  

Authors

  • Nathalia Franco UFRGS
  • Emanuelle BortolottoDegregori Universidade Federal do Rio Grande do Sul
  • Natália Fantinel de Mattos Universidade de Passo Fundo
  • Luciana Gonçalves Teixeira Universidade Federal do Rio Grande do Sul
  • Matheus Pippi da Rosa Universidade Federal do Rio Grande do Sul
  • Emerson Antonio Contesini Universidade Federal do Rio Grande do Sul

DOI:

https://doi.org/10.31533/pubvet.v13n2a279.1-8

Keywords:

anthracyclines, cardiotoxicity, chemotherapy, doxorubicin, nano-oncology

Abstract

Veterinary oncology has gained space since pet’s population is getting older, and, subsequently, developing neoplasias. Antineoplasic antibiotics’ class, or anthracyclines, comprehends a pharmacologic group produced by different species of gram-positive bacteria Streptomyces, and its action mechanism occurs mostly due to double-tape DNA intercalation, inducing cellular apoptosis. The most recognized agents are doxorubicin (DOX), mitoxantrone (MIT), actinomycin-D (ACT-D), bleomycin and epirubicin (EPI), however, due to its cytotoxic effects, mostly cardiotoxicity, new agents and administration forms have been developed, aiming to reduce adverse effects and potentialize antineoplastic activity. Nano-oncology highlights new technologies development, as liposomes, metal and polymer nanoparticles, besides recent development of pharmacogenetics and pharmacogenomics in veterinary field. The aim of this review is to align excellent anthracyclines antineoplastic capacity associated to new agents, technologies and administration forms and its applicability and status in pet’s medicine.

 

Published

2019-03-08

Issue

Section

Medicina veterinária

How to Cite

Chemotherapeutic antibiotics use in oncology in small animals: Review  . (2019). Pubvet, 13(02). https://doi.org/10.31533/pubvet.v13n2a279.1-8

Most read articles by the same author(s)